Patents Represented by Attorney SaraLynn Mandel
-
Patent number: 5416260Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs.Type: GrantFiled: November 9, 1990Date of Patent: May 16, 1995Assignee: University of North Carolina at Chapel HillInventors: Beverly H. Koller, Oliver Smithies
-
Patent number: 5413923Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies.Type: GrantFiled: December 11, 1992Date of Patent: May 9, 1995Assignees: Cell Genesys, Inc., Univ. of North Carolina at Chapel HillInventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies
-
Patent number: 5144021Abstract: A method and media for producing bacterial cellulose under agitated culture conditions resulting in sustained production over an average of 70 hours of at least 0.1 g/liter per hour are achieved. A unique reticulated cellulose product is produced using the methods and conditions claimed, and may be in the form of a sheet characterized by substantial resistance to densification and great tensile strength when produced by sheet forming means.Strains of Acetobacter that are stable under agitated culture conditions and that exhibit substantially reduced gluconic and keto-gluconic acid production are described.Type: GrantFiled: January 30, 1991Date of Patent: September 1, 1992Assignee: Weyerhaeuser CompanyInventors: Ben-Bassat Arie, Robert Bruner, Sharon Shoemaker, Yehoshua Aloni, Harry Wong, Donald C. Johnson, Amar Neogi
-
Patent number: 5137877Abstract: The present invention provides novel N-substituted hydrazine bifunctional compounds, novel N-subhstituted hydrazone derivatives of a cytotoxic reagent incorporating the bifunctional compounds, novel conjugates containing at least one cytotoxic reagent molecule reacted with the bifunctional compound and bound to a molecule reactive with a target cell population, methods for their production, and pharmaceutical compositions and methods for delivering cytotoxic reagents to a target population of cells. The hydrazone bonds of the conjugates of the invention permit the release of free cytotoxic reagent from the conjugates in the acidic external or internal environment of the target cells. The bifunctional compounds, derivatives, conjugates and methods of the invention are useful in antibody-or ligand-mediated drug delivery systems for the perferential killing of a target cell population to treat diseases such as cancers, infections and autoimmune disorders.Type: GrantFiled: May 14, 1990Date of Patent: August 11, 1992Assignee: Bristol-Myers SquibbInventors: Takushi Kaneko, David Willner, Ivo Monkovic, Robert S. Greenfield, Gary R. Braslawsky
-
Patent number: 5135956Abstract: A method for treating or preventing neuronal injury in a mammal, comprising the step of administering in vivo a therapeutically effective amount of a long-chain fatty alcohol having from about 23 to about 29 carbon atoms or prodrug esters thereof. Also disclosed are pharmacological compositions containing from 0.01 mg/kg to about 20 mg/kg of the fatty alcohol. The method and compositions are useful in: treating traumatic injury, chemical injury and injury due to disease; promoting and accelerating recovery of behavioral function after such injury; preventing neuronal injury or death; improving training and memory functions; and protecting neurons against injury.Type: GrantFiled: October 13, 1989Date of Patent: August 4, 1992Assignee: The Regents of the University of CaliforniaInventors: Jacques Borg, Carl W. Cotman, J. Patrick Kesslak
-
Patent number: 5134075Abstract: The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon, breast, ovary and lung, as well as melanomas and sarcomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 100,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.Type: GrantFiled: February 17, 1989Date of Patent: July 28, 1992Assignee: Oncogen Limited PartnershipInventors: Karl E. Hellstrom, Ingegerd Hellstrom, Hans Marquardt, Yoshitaka Yoneyama
-
Patent number: 5110600Abstract: Retrovirally-infected cells are selectively killed as compared with uninfected cells using an effective amount of amino acid analogs of naturally occurring amino acids, such as L-canavanine (an analog of arginine).Type: GrantFiled: January 25, 1988Date of Patent: May 5, 1992Assignee: The Regents of the University of CaliforniaInventor: Melvin H. Green
-
Patent number: 5084560Abstract: Novel pH-sensitive immunoconjugates which dissociate in low-pH tumor tissue, comprising a chemotherapeutic agent and an antibody reactive with a tumor-associated antigen are described. The chemotherapeutic agent is coupled to the antibody by a link which is unstable in low pH. The link may comprise a spacer consisting of a polyamino acid. Representative antibodies for use in these immunoconjugates include monoclonal antibodies which are not internalized by tumor cells.Type: GrantFiled: August 7, 1990Date of Patent: January 28, 1992Assignee: OncogenInventors: Karl E. Hellstrom, Ingegerd E. Hellestrom, Efraim Lavie
-
Patent number: 4997913Abstract: Novel pH-sensitive immunoconjugates which dissociate in low-pH tumor tissue, comprising a chemotherapeutic agent and an antibody reactive with a tumor-associated antigen are described. The chemotherapeutic agent is coupled to the antibody by a link which is unstable in low pH. The link may comprise a spacer consisting of a polyamino acid. Representative antibodies for use in these immunoconjugates include monoclonal antibodies which are not internalized by tumor cells.Type: GrantFiled: May 12, 1987Date of Patent: March 5, 1991Assignee: OncogenInventors: Karl E. Hellstrom, Ingegerd E. Hellstrom, Efraim Lavie
-
Patent number: 4859474Abstract: A process for producing fructose sweetened cereal products by enzymatically converting a portion of the cellulose fraction in a cereal comprising cereal; fiber to fructose using cellulase and glucose isomerase is claimed. The process may be carried out at moisture contents exceeding 25% (w/w) and moisture contents between about 40% to 80% are preferred.Type: GrantFiled: September 28, 1987Date of Patent: August 22, 1989Assignee: Nabisco/Cetus Food Biotechnology Research PartnershipInventors: Saul L. Neidleman, John A. Maselli
-
Patent number: 4792407Abstract: A method of oxidizing organic compounds in aqueous solutions by using in combination ozone, hydrogen peroxide and ultraviolet radiation is provided.Type: GrantFiled: February 18, 1988Date of Patent: December 20, 1988Assignee: Ultrox InternationalInventors: Jack D. Zeff, Eriks Leitis